X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is being developed to mediate removal of excess cholesterol that damages the kidneys’ filtration system (renal glomeruli podocytes) in patients with Diabetic Kidney Disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Nephrology Product Name: VAR 200
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
The net proceeds will be used to focus on the clinical development of IC 100-08, a novel humanized IgG4 monoclonal antibody. Currently, it is being evaluated in the preclinical studies for the treatment of obesity.
Lead Product(s): IC 100-08
Therapeutic Area: Nutrition and Weight Loss Product Name: IC 100-08
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 29, 2024
Details:
VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready drug in development which has potential to treat multiple kidney diseases, including diabetic kidney disease, rare kidney diseases, FSGS (focal segmental glomerulosclerosis) and Alport syndrome.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Nephrology Product Name: VAR 200
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: George Clinical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
VAR 200 (2HPβCD) is a cholesterol efflux mediator in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system. VAR 200 passively and actively removes excess lipids from the kidney and has potential to treat other glomerular diseases.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Nephrology Product Name: VAR 200
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
The support will enable company to advance clinical evaluation of cholesterol efflux mediator candidate (VAR 200) in patients with orphan renal disease, FSGS, and to progress the inflammasome ASC inhibitor candidate (IC 100) into Phase 1 trials.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Nephrology Product Name: VAR 200
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Larkspur Health Acquisition
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Agreement September 27, 2022
Details:
IC 100, a novel monoclonal antibody inflammasome ASC inhibitor, targets multiple types of inflammasomes, including NLRP1, to block initiation and perpetuation of damaging chronic inflammation.
Lead Product(s): IC 100
Therapeutic Area: Neurology Product Name: IC 100
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Larkspur Health Acquisition Corp
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
IC 100, a novel monoclonal antibody inflammasome ASC inhibitor, targets multiple types of inflammasomes to block initiation and perpetuation of damaging chronic inflammation.
Lead Product(s): IC 100
Therapeutic Area: Neurology Product Name: IC 100
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Larkspur Health Acquisition Corp
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
IC 100, a CNS-penetrating monoclonal ASC Inhibitor, targets multiple types of inflammasomes to block initiation and perpetuation of damaging chronic inflammation.
Lead Product(s): IC 100
Therapeutic Area: Neurology Product Name: IC 100
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Miami
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding July 27, 2022
Details:
ZyVersa's management team has deep scientific and operational experience, and the company has two exciting assets, IC 100 for inflammatory diseases and VAR 200 for renal diseases.
Lead Product(s): 2-hydroxypropyl-beta Cyclodextrin
Therapeutic Area: Nephrology Product Name: VAR 200
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Larkspur Health Acquisition Corp.
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 20, 2022
Details:
ZyVersa is well positioned in the rapidly emerging inflammasome spwith IC 100, and in kidney disease with a first-in-class phase 2a-ready cholesterol efflux mediator for treatment (VAR 200) of orphan renal disease FSGS and other kidney diseases.
Lead Product(s): IC 100
Therapeutic Area: Neurology Product Name: IC 100
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
